Biogen
European Regulators Reject Eisai and Biogen’s Alzheimer’s Drug Leqembi
Eisai, Biogen, Leqembi, Alzheimer’s disease, European Medicines Agency, drug rejection
Biogen and Sage Therapeutics Discontinue Development of SAGE-324 for Essential Tremor Following Mid-Stage Trial Failure
Biogen, Sage Therapeutics, SAGE-324, Essential Tremor, Mid-Stage Trial, Neurological Disorder, GABA Receptor Modulator, Clinical Development
Ionis Advances to Phase 3 Trial for Angelman Syndrome Treatment ION582
Ionis Pharmaceuticals, Angelman syndrome, ION582, Phase 3 trial, antisense oligonucleotides, neurological conditions, rare diseases, Biogen, Ultragenyx Pharmaceutical
Rovi Receives Acquisition Offers for CDMO Unit Worth €2B to €3B
Rovi, CDMO, Acquisition Offers, Private Equity, Biogen, Deal Making
Eisai Seeks FDA Approval for Monthly IV Dosing of LEQEMBI for Alzheimer’s Disease Treatment
LEQEMBI, Eisai, FDA, Alzheimer’s disease, monthly IV dosing, subcutaneous autoinjector, lecanemab-irmb, Biogen
Italian Antitrust Agency Investigates Novartis, Biogen, and Others Over Lucentis Biosimilar
Italian Competition Authority, Novartis, Biogen, Samsung Bioepis, Genentech, Lucentis, Byooviz, Biosimilar, Antitrust Probe
Biogen and Ionis’ ALS Treatment Qalsody Receives European Commission Approval
Biogen, Ionis, Qalsody, ALS, European Commission, Marketing Authorization, Rare Disease, SOD1-ALS, Neurofilament, Clinical Trials
Biogen Expands Immunology Portfolio with $1.15 Billion Acquisition of HI-Bio
Biogen, HI-Bio, acquisition, immunology, $1.15 billion, expansion, therapeutics, drug development
FDA Greenlights Biocon Biologics and Biogen’s Eylea Biosimilars: A New Era in Ophthalmology
FDA, Eylea, biosimilars, Biocon Biologics, Biogen, ophthalmology, aflibercept, regulatory approval
Biogen Discontinues Ionis Collaboration on ALS and Angelman Syndrome Treatments Following Early Clinical Results
Biogen, Ionis, ALS, Angelman Syndrome, collaboration, discontinuation, early-stage readouts, clinical trials, treatments, neurological disorders.